Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23944081,tmax,"The main parameters were: tmax was 10 min, t1/2beta was (183. 93 52. 75) min, CL/F was (0. 426 +/- 0. 194) L . min-1 .",[Study on pharmacokinetics and in vitro/in vivo correlation of menthol in Zhike Chuanbei Pipa dropping pills in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944081/),min,10,4359,DB00825,Menthol
,23944081,t1/2beta,"The main parameters were: tmax was 10 min, t1/2beta was (183. 93 52. 75) min, CL/F was (0. 426 +/- 0. 194) L . min-1 .",[Study on pharmacokinetics and in vitro/in vivo correlation of menthol in Zhike Chuanbei Pipa dropping pills in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944081/),min,183. 93,4360,DB00825,Menthol
,23944081,CL/F,"The main parameters were: tmax was 10 min, t1/2beta was (183. 93 52. 75) min, CL/F was (0. 426 +/- 0. 194) L . min-1 .",[Study on pharmacokinetics and in vitro/in vivo correlation of menthol in Zhike Chuanbei Pipa dropping pills in rats]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944081/),[l] / [min],0. 426,4361,DB00825,Menthol
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,8.53,11633,DB00825,Menthol
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,6.69,11634,DB00825,Menthol
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,4.35,11635,DB00825,Menthol
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,8.67,11636,DB00825,Menthol
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,13.02,11637,DB00825,Menthol
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,14.78,11638,DB00825,Menthol
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,234.9,11639,DB00825,Menthol
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,525.4,11640,DB00825,Menthol
,12235445,inhibition constant [K(i)],"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μg] / [ml],35.9,15936,DB00825,Menthol
,12235445,K(i),"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],87.0,15937,DB00825,Menthol
,12235445,K(i),"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],124.0,15938,DB00825,Menthol
,12235445,K(i),Ascorbyl palmitate was more potent (K(i) = 12.3 +/- 0.5 micromol/L).,Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],12.3,15939,DB00825,Menthol
,23469686,maximum concentration (Cmax),"Following i.v. bolus administration, terpinen-4-ol rapidly distributed into the dermis and reached relatively low levels with an average maximum concentration (Cmax) of 0.10 +/- 0.06 microg/ml in comparison with a plasma Cmax of 6.30 +/- 1.90 microg/ml.",Plasma and dermal pharmacokinetics of terpinen-4-ol in rats following intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469686/),[μg] / [ml],0.10,33212,DB00825,Menthol
,23469686,plasma Cmax,"Following i.v. bolus administration, terpinen-4-ol rapidly distributed into the dermis and reached relatively low levels with an average maximum concentration (Cmax) of 0.10 +/- 0.06 microg/ml in comparison with a plasma Cmax of 6.30 +/- 1.90 microg/ml.",Plasma and dermal pharmacokinetics of terpinen-4-ol in rats following intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469686/),[μg] / [ml],6.30,33213,DB00825,Menthol
,19624007,tmax,"The parameters tmax, cmax, AUC, t 1/2(beta) were 0.68 h, 27.32 ng x mL(-1), 132.68 ng x h x mL(-1), 3.1076 h.",[Effect of borneol/mentholum eutectic mixture on nasal-brain delivery of neurotoxin loaded nanoparticles]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624007/),h,0.68,33918,DB00825,Menthol
,19624007,cmax,"The parameters tmax, cmax, AUC, t 1/2(beta) were 0.68 h, 27.32 ng x mL(-1), 132.68 ng x h x mL(-1), 3.1076 h.",[Effect of borneol/mentholum eutectic mixture on nasal-brain delivery of neurotoxin loaded nanoparticles]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624007/),[h·ng] / [ml],132.68,33919,DB00825,Menthol
,19624007,AUC,"The parameters tmax, cmax, AUC, t 1/2(beta) were 0.68 h, 27.32 ng x mL(-1), 132.68 ng x h x mL(-1), 3.1076 h.",[Effect of borneol/mentholum eutectic mixture on nasal-brain delivery of neurotoxin loaded nanoparticles]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624007/),[h·ng] / [ml],132.68,33920,DB00825,Menthol
,19624007,t 1/2(beta),"The parameters tmax, cmax, AUC, t 1/2(beta) were 0.68 h, 27.32 ng x mL(-1), 132.68 ng x h x mL(-1), 3.1076 h.",[Effect of borneol/mentholum eutectic mixture on nasal-brain delivery of neurotoxin loaded nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624007/),h,3.1076,33921,DB00825,Menthol
,14716748,steady state flux,"Ex vivo steady state flux of AZT across rat skin from gel was 2.26 mg cm(-2) h(-1), which is sufficient to achieve therapeutic plasma concentrations.","Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716748/),[mg] / [(cm)^2·h],2.26,46606,DB00825,Menthol
,21502034,steady-state flux,"Among all gel formulations, gel containing cineole and menthol as penetration enhancers attained a steady-state flux of 5.9 mg/cm(2)/h and 5.4 mg/cm(2)/h of zidovudine, respectively, leading to plasma concentration in the therapeutic range.",Effect of penetration enhancers on gel formulation of Zidovudine: in vivo and ex vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502034/),[mg] / [cm(2)·h],5.9,46662,DB00825,Menthol
,21502034,steady-state flux,"Among all gel formulations, gel containing cineole and menthol as penetration enhancers attained a steady-state flux of 5.9 mg/cm(2)/h and 5.4 mg/cm(2)/h of zidovudine, respectively, leading to plasma concentration in the therapeutic range.",Effect of penetration enhancers on gel formulation of Zidovudine: in vivo and ex vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502034/),[mg] / [cm(2)·h],5.4,46663,DB00825,Menthol
,20863003,relative bioavailability,The relative bioavailability was 121.4 +/- 10.6% for AUC(0-infinity).,Bioequivalence evaluation of menthol after oral administration of peppermint oil soft capsules in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20863003/),%,121.4,55362,DB00825,Menthol
,18611395,K(i),"Citral and geraniol strongly inhibited CYP2B6 hydroxylase activity in a competitive manner, with K(i) values of 6.8 and 10.3muM, respectively, which are higher than the K(i) (1.8muM) of the well-known CYP2B6-selective inhibitor thio-TEPA.",The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611395/),muM,6.8,67153,DB00825,Menthol
,18611395,K(i),"Citral and geraniol strongly inhibited CYP2B6 hydroxylase activity in a competitive manner, with K(i) values of 6.8 and 10.3muM, respectively, which are higher than the K(i) (1.8muM) of the well-known CYP2B6-selective inhibitor thio-TEPA.",The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611395/),muM,10.3,67154,DB00825,Menthol
,18611395,K(i),"Citral and geraniol strongly inhibited CYP2B6 hydroxylase activity in a competitive manner, with K(i) values of 6.8 and 10.3muM, respectively, which are higher than the K(i) (1.8muM) of the well-known CYP2B6-selective inhibitor thio-TEPA.",The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611395/),muM,1.8,67155,DB00825,Menthol
,24490806,oral bioavailability,"Fexofenadine hydrochloride (FXD) is a slightly soluble, bitter-tasting, drug having an oral bioavailability of 35%.","Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),%,35,70023,DB00825,Menthol
,24490806,T(max),The maximum plasma concentration is reached 2.6 h (T(max)) post-dose.,"Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),h,2.6,70024,DB00825,Menthol
,24490806,f(2),Drug release profiles of F23 and the phenylalanine-containing Allegra(®) ODT were similar (f(2) = 96).,"Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),,96,70025,DB00825,Menthol
,27924817,Jss,Average Jss (μg/cm2/h) from formulations were: nicotine in PG (24 mg/ml): 3.97; commercial e-liquid containing menthol (25 mg/ml nicotine): 10.2; commercial e-liquid containing limonene (25 mg/ml nicotine): 23.7; neat nicotine: 175.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),[μg] / [cm2·h],3.97,85314,DB00825,Menthol
,27924817,Jss,Average Jss (μg/cm2/h) from formulations were: nicotine in PG (24 mg/ml): 3.97; commercial e-liquid containing menthol (25 mg/ml nicotine): 10.2; commercial e-liquid containing limonene (25 mg/ml nicotine): 23.7; neat nicotine: 175.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),[μg] / [cm2·h],10.2,85315,DB00825,Menthol
,27924817,Jss,Average Jss (μg/cm2/h) from formulations were: nicotine in PG (24 mg/ml): 3.97; commercial e-liquid containing menthol (25 mg/ml nicotine): 10.2; commercial e-liquid containing limonene (25 mg/ml nicotine): 23.7; neat nicotine: 175.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),[μg] / [cm2·h],23.7,85316,DB00825,Menthol
,27924817,Jss,Average Jss (μg/cm2/h) from formulations were: nicotine in PG (24 mg/ml): 3.97; commercial e-liquid containing menthol (25 mg/ml nicotine): 10.2; commercial e-liquid containing limonene (25 mg/ml nicotine): 23.7; neat nicotine: 175.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),[μg] / [cm2·h],175,85317,DB00825,Menthol
,27924817,lag times,E-liquid lag times ranged from 5 to 10 h.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),h,5 to 10,85318,DB00825,Menthol
≈,27924817,Absorbed fraction,Absorbed fraction of nicotine from finite doses was ≈0.3 at 48 h.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),,0.3,85319,DB00825,Menthol
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,31.49,85825,DB00825,Menthol
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,22.95,85826,DB00825,Menthol
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,1.99,85827,DB00825,Menthol
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,1.76,85828,DB00825,Menthol
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,11.77,85829,DB00825,Menthol
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,10.44,85830,DB00825,Menthol
,25482264,maximum plasma drug concentration (Cmax),The maximum plasma drug concentration (Cmax) of total methoxyflavones was 218.08ng/ml with Tmax at 8h.,A monolithic drug-in-adhesive patch of methoxyflavones from Kaempferia parviflora: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25482264/),[ng] / [ml],218.08,89736,DB00825,Menthol
,25482264,Tmax,The maximum plasma drug concentration (Cmax) of total methoxyflavones was 218.08ng/ml with Tmax at 8h.,A monolithic drug-in-adhesive patch of methoxyflavones from Kaempferia parviflora: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25482264/),h,8,89737,DB00825,Menthol
,11041263,systemic bioavailability,"The remaining FP in the gel 6 h after the application was 60% of the initial loading and the systemic bioavailability over the 6 h application was about 10%, suggesting that the rest (30%) had accumulated in the skin tissues.",Effect of l-menthol-ethanol-water system on the systemic absorption of flurbiprofen after repeated topical applications in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041263/),%,10,96196,DB00825,Menthol
,11041263,systemic bioavailability,"The remaining FP in the gel 6 h after the application was 60% of the initial loading and the systemic bioavailability over the 6 h application was about 10%, suggesting that the rest (30%) had accumulated in the skin tissues.",Effect of l-menthol-ethanol-water system on the systemic absorption of flurbiprofen after repeated topical applications in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041263/),%,30,96197,DB00825,Menthol
,23307595,relative bioavailability,"The final patch showed a high efficiency, with a relative bioavailability of 1,494%.",Development and evaluation of α-asarone transdermal patches based on hot-melt pressure-sensitive adhesives. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307595/),%,"1,494",111998,DB00825,Menthol
,12915954,t(max),Co-administration of menthol resulted in an increase of caffeine t(max) values from 43.6+/-20.6 min (mean+/-SD) to 76.4+/-28.0 min ( P<0.05).,Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915954/),min,43.6,116060,DB00825,Menthol
,12915954,t(max),Co-administration of menthol resulted in an increase of caffeine t(max) values from 43.6+/-20.6 min (mean+/-SD) to 76.4+/-28.0 min ( P<0.05).,Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915954/),min,76.4,116061,DB00825,Menthol
,15567287,maximum solubility,"The poloxamer gel with menthol/ibuprofen ratio of 1:9 and higher than 15% poloxamer 188 showed the maximum solubility of ibuprofen, 1.2mg/ml.",Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15567287/),[mg] / [ml],1.2,133042,DB00825,Menthol
,15567287,solubility,The ibuprofen-loaded liquid suppository [P 188/menthol/ibuprofen (15/0.25/2.5%)] with the maximum ibuprofen solubility of 1.2mg/ml was administered easily to the anus and to remain at the administered site without leakage after the dose.,Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15567287/),[mg] / [ml],1.2,133043,DB00825,Menthol
,11455677,maximum plasma levels,The mean maximum plasma levels for menthol were 1196 ng/ml after administration of the test medication and 1492 ng/ml after administration of the reference medication.,Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11455677/),[ng] / [ml],1196,134312,DB00825,Menthol
,11455677,maximum plasma levels,The mean maximum plasma levels for menthol were 1196 ng/ml after administration of the test medication and 1492 ng/ml after administration of the reference medication.,Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11455677/),[ng] / [ml],1492,134313,DB00825,Menthol
,11455677,bioavailability,"The bioavailability with respect to the AUC was comparable after administration of test and reference preparation, the 90% confidence interval was 97 to 105%.",Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11455677/),%,97 to 105,134314,DB00825,Menthol
,11455677,maximum concentration,After application of the enteric coated form the maximum concentration was reached significantly later (3.0 h vs. 1.7 h) compared to the immediate release capsule.,Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11455677/),h,3.0,134315,DB00825,Menthol
,11455677,maximum concentration,After application of the enteric coated form the maximum concentration was reached significantly later (3.0 h vs. 1.7 h) compared to the immediate release capsule.,Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11455677/),h,1.7,134316,DB00825,Menthol
,11455677,maxima,After application of the test medication the maxima of 14 ng/ml for both formulations were reached later (2.5 h vs. 1.3 h).,Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11455677/),[ng] / [ml],14,134317,DB00825,Menthol
,2726994,relative bioavailability,"The relative bioavailability of the model substance 1,8-cineole obtained by using an applicator was 320% as compared with that obtained by using an occlusive dressing.",[Skin absorption of volatile oils. Pharmacokinetics]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2726994/),%,320,137021,DB00825,Menthol
<,24597733,ED90,Compound 45 demonstrated robust efficacy in both pharmacodynamic models with ED90 values <3 mg/kg.,Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24597733/),[mg] / [kg],3,137160,DB00825,Menthol
less,22010981,friability,"The sildenafil lactate-loaded orally disintegrating tablet prepared with 45 mg/tab of menthol and 1.5 mg/tab of colloidal silica gave a hardness of 3-4 KP, friability less than 0.5% and disintegration time less than 30 s, suggesting that it was a practical and commercial product with good tablet property and excellent efficacy.",Development of sildenafil-loaded orally disintegrating tablet with new lactate salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010981/),%,0.5,137720,DB00825,Menthol
less,22010981,disintegration time,"The sildenafil lactate-loaded orally disintegrating tablet prepared with 45 mg/tab of menthol and 1.5 mg/tab of colloidal silica gave a hardness of 3-4 KP, friability less than 0.5% and disintegration time less than 30 s, suggesting that it was a practical and commercial product with good tablet property and excellent efficacy.",Development of sildenafil-loaded orally disintegrating tablet with new lactate salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010981/),s,30,137721,DB00825,Menthol
,28008227,percentage relative bioavailability,BH.2HCl-optimized buccal mucoadhesive formulation showed percentage relative bioavailability of 177%.,"Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008227/),%,177,138729,DB00825,Menthol
,10460066,plasma half-life,"The plasma half-life of menthol glucuronide averaged 56.2 minutes (95% confidence interval [CI], 51.0 to 61.5) and 42.6 minutes (95% CI, 32.5 to 52.7) in menthol capsule and mint candy/mint tea conditions, respectively (P < .05).",Disposition kinetics and effects of menthol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460066/),min,56.2,142064,DB00825,Menthol
,10460066,plasma half-life,"The plasma half-life of menthol glucuronide averaged 56.2 minutes (95% confidence interval [CI], 51.0 to 61.5) and 42.6 minutes (95% CI, 32.5 to 52.7) in menthol capsule and mint candy/mint tea conditions, respectively (P < .05).",Disposition kinetics and effects of menthol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460066/),min,42.6,142065,DB00825,Menthol
,10460066,Urinary recovery,"Urinary recovery of menthol as the glucuronide averaged 45.6 and 56.6% for menthol capsule and mint candy/tea, respectively (difference not significant).",Disposition kinetics and effects of menthol. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460066/),%,45.6,142066,DB00825,Menthol
,10460066,Urinary recovery,"Urinary recovery of menthol as the glucuronide averaged 45.6 and 56.6% for menthol capsule and mint candy/tea, respectively (difference not significant).",Disposition kinetics and effects of menthol. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460066/),%,56.6,142067,DB00825,Menthol
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,407.10,151490,DB00825,Menthol
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,389.20,151491,DB00825,Menthol
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,285.08,151492,DB00825,Menthol
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,193.10,151493,DB00825,Menthol
,30284674,time to reach the maximum concentration (Tmax),The time to reach the maximum concentration (Tmax) of IC-PO was significantly longer compared to SI-PO with a median (IQR) of 360 (360-405) versus 180 (120-180) min.,A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284674/),min,360,152007,DB00825,Menthol
,30284674,time to reach the maximum concentration (Tmax),The time to reach the maximum concentration (Tmax) of IC-PO was significantly longer compared to SI-PO with a median (IQR) of 360 (360-405) versus 180 (120-180) min.,A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284674/),min,180,152008,DB00825,Menthol
,30284674,lag time (Tlag),The lag time (Tlag) was significantly longer with a median (IQR) of 225 (204-284) for IC-PO compared to 37 (6-65) min for SI-PO.,A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284674/),min,225,152009,DB00825,Menthol
,30284674,lag time (Tlag),The lag time (Tlag) was significantly longer with a median (IQR) of 225 (204-284) for IC-PO compared to 37 (6-65) min for SI-PO.,A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284674/),min,37,152010,DB00825,Menthol
,30284674,areas under the,The areas under the menthol glucuronide plasma concentration-time curves were significantly smaller with a median (IQR) of 2331 μg h/L (2006-2510) for IC-PO compared to 2623 μg h/L (2471-2920) for SI-PO.,A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284674/),[h·μg] / [l],2331,152011,DB00825,Menthol
,30284674,areas under the,The areas under the menthol glucuronide plasma concentration-time curves were significantly smaller with a median (IQR) of 2331 μg h/L (2006-2510) for IC-PO compared to 2623 μg h/L (2471-2920) for SI-PO.,A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284674/),[h·μg] / [l],2623,152012,DB00825,Menthol
,30284674,plasma concentration-time curves,The areas under the menthol glucuronide plasma concentration-time curves were significantly smaller with a median (IQR) of 2331 μg h/L (2006-2510) for IC-PO compared to 2623 μg h/L (2471-2920) for SI-PO.,A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284674/),[h·μg] / [l],2331,152013,DB00825,Menthol
,30284674,plasma concentration-time curves,The areas under the menthol glucuronide plasma concentration-time curves were significantly smaller with a median (IQR) of 2331 μg h/L (2006-2510) for IC-PO compared to 2623 μg h/L (2471-2920) for SI-PO.,A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284674/),[h·μg] / [l],2623,152014,DB00825,Menthol
,22311961,peak concentrations of nicotine in plasma (C(max)),"Following single-cigarette smoke inhalation, mentholated cigarettes significantly decreased the mean peak concentrations of nicotine in plasma (C(max)) from 27.1 to 9.61 ng/ml and the total area under the plasma concentration-time curves (AUC) from 977 to 391 ng min/ml as compared with those after nonmentholated cigarette smoke inhalation.",Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22311961/),[ng] / [ml],27.1 to 9.61,178059,DB00825,Menthol
,22311961,total area under the plasma concentration-time curves (AUC),"Following single-cigarette smoke inhalation, mentholated cigarettes significantly decreased the mean peak concentrations of nicotine in plasma (C(max)) from 27.1 to 9.61 ng/ml and the total area under the plasma concentration-time curves (AUC) from 977 to 391 ng min/ml as compared with those after nonmentholated cigarette smoke inhalation.",Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22311961/),[min·ng] / [ml],977 to 391,178060,DB00825,Menthol
,22311961,AUC ratio,"Interestingly, there was a significant increase in the cotinine to nicotine AUC ratio from 13.8 for the nonmentholated to 21.1 for the mentholated cigarette.",Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22311961/),,13.8,178061,DB00825,Menthol
,22311961,AUC ratio,"Interestingly, there was a significant increase in the cotinine to nicotine AUC ratio from 13.8 for the nonmentholated to 21.1 for the mentholated cigarette.",Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22311961/),,21.1,178062,DB00825,Menthol
,8866111,distribution half-life,"The elimination of this fragrance compound from the blood is biphasic, with a mean distribution half-life of 6.7 min and an elimination half-life of 104.6 min.","Pharmacokinetic studies of the fragrance compound 1,8-cineol in humans during inhalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866111/),min,6.7,179984,DB00825,Menthol
,8866111,elimination half-life,"The elimination of this fragrance compound from the blood is biphasic, with a mean distribution half-life of 6.7 min and an elimination half-life of 104.6 min.","Pharmacokinetic studies of the fragrance compound 1,8-cineol in humans during inhalation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866111/),min,104.6,179985,DB00825,Menthol
,12244893,maximum plasma levels,The mean maximum plasma levels for menthol were 1196 ng/ml after administration of the test medication and 1492 ng/ml after administration of the reference medication.,[Pharmacokinetics of carvone and menthol after administration of peppermint oil and caraway oil containing enteric formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12244893/),[ng] / [ml],1196,180923,DB00825,Menthol
,12244893,maximum plasma levels,The mean maximum plasma levels for menthol were 1196 ng/ml after administration of the test medication and 1492 ng/ml after administration of the reference medication.,[Pharmacokinetics of carvone and menthol after administration of peppermint oil and caraway oil containing enteric formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12244893/),[ng] / [ml],1492,180924,DB00825,Menthol
,12244893,bioavailability,"The bioavailability with respect to the AUC was comparable after administration of test and reference preparation, the 90% confidence interval was 97 to 105%.",[Pharmacokinetics of carvone and menthol after administration of peppermint oil and caraway oil containing enteric formulation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12244893/),%,97 to 105,180925,DB00825,Menthol
,12244893,maximum concentration,After application of the enteric coated form the maximum concentration was reached significantly later (3.0 h vs. 1.7 h) compared to the immediate release capsule.,[Pharmacokinetics of carvone and menthol after administration of peppermint oil and caraway oil containing enteric formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12244893/),h,3.0,180926,DB00825,Menthol
,12244893,maximum concentration,After application of the enteric coated form the maximum concentration was reached significantly later (3.0 h vs. 1.7 h) compared to the immediate release capsule.,[Pharmacokinetics of carvone and menthol after administration of peppermint oil and caraway oil containing enteric formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12244893/),h,1.7,180927,DB00825,Menthol
,12244893,maxima,After application of the test medication the maxima of 14 ng/ml for both formulations were reached later (2.5 h vs. 1.3 h).,[Pharmacokinetics of carvone and menthol after administration of peppermint oil and caraway oil containing enteric formulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12244893/),[ng] / [ml],14,180928,DB00825,Menthol
,16207608,maximum solubility,"The poloxamer gel with menthol/ibuprofen ratio of 1:9 and higher than 15% poloxamer 188 showed the maximum solubility of ibuprofen, 1.2 mg/mL.",Enhanced oral bioavailability of ibuprofen in rats by poloxamer gel using poloxamer 188 and menthol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207608/),[mg] / [ml],1.2,225815,DB00825,Menthol
,30564074,extraction recoveries,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),%,69-84,227547,DB00825,Menthol
,30564074,enrichment factors,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),,345-420,227548,DB00825,Menthol
,26270949,lag time,"Following a dose of PMO, a substantial lag time (range 1-4 h) was seen in all subjects for the appearance of menthol which in turn, produced a delayed time of peak (Tmax=5.3 ± 2.4 h) plasma concentration (Cmax=698.2 ± 245.4 ng/mL).",Systemic exposure to menthol following administration of peppermint oil to paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270949/),h,1-4,233646,DB00825,Menthol
,26270949,time of peak (Tmax,"Following a dose of PMO, a substantial lag time (range 1-4 h) was seen in all subjects for the appearance of menthol which in turn, produced a delayed time of peak (Tmax=5.3 ± 2.4 h) plasma concentration (Cmax=698.2 ± 245.4 ng/mL).",Systemic exposure to menthol following administration of peppermint oil to paediatric patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270949/),h,5.3,233647,DB00825,Menthol
,26270949,Cmax,"Tmax and Tlag were significantly more variable than the two exposure parameters; Cmax, mean residence time and total area under the curve (AUC=4039.7 ± 583.8 ng/mL × h) which had a coefficient of variation of <20%.",Systemic exposure to menthol following administration of peppermint oil to paediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270949/),[ng] / [h·ml],4039.7,233648,DB00825,Menthol
,26270949,total area under the curve (,"Tmax and Tlag were significantly more variable than the two exposure parameters; Cmax, mean residence time and total area under the curve (AUC=4039.7 ± 583.8 ng/mL × h) which had a coefficient of variation of <20%.",Systemic exposure to menthol following administration of peppermint oil to paediatric patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270949/),[ng] / [h·ml],4039.7,233649,DB00825,Menthol
,26270949,AUC,"Tmax and Tlag were significantly more variable than the two exposure parameters; Cmax, mean residence time and total area under the curve (AUC=4039.7 ± 583.8 ng/mL × h) which had a coefficient of variation of <20%.",Systemic exposure to menthol following administration of peppermint oil to paediatric patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270949/),[ng] / [h·ml],4039.7,233650,DB00825,Menthol
,21484670,CMAX,"The average value of CMAX was 18.97 ± 2.71 ng/µL with a TMAX at 20.00 ± 0.00 min for borneol after oral administration of the drop pills; for menthol, the average value of CMAX was 79.02 ± 11.40 ng/µL with a TMAX at 25.00 ± 4.40 min.",Pharmacokinetic study of borneol and menthol in rats after oral administration of qingyan drop pills. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21484670/),[ng] / [μl],18.97,234969,DB00825,Menthol
,21484670,CMAX,"The average value of CMAX was 18.97 ± 2.71 ng/µL with a TMAX at 20.00 ± 0.00 min for borneol after oral administration of the drop pills; for menthol, the average value of CMAX was 79.02 ± 11.40 ng/µL with a TMAX at 25.00 ± 4.40 min.",Pharmacokinetic study of borneol and menthol in rats after oral administration of qingyan drop pills. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21484670/),[ng] / [μl],79.02,234970,DB00825,Menthol
,31163413,m,"By operating the drift tube above about 130 Td, there are characteristic product ions for menthone, menthofuran and menthol, namely m/z 155.14 (protonated menthone), m/z 151.11 (protonated menthofuran), m/z 139.15 (loss of H2O from protonated menthol) and m/z 83.09 (a fragment ion, C6H11 +, from menthol).",Proton transfer reaction time-of-flight mass spectrometric measurements of volatile compounds contained in peppermint oil capsules of relevance to real-time pharmacokinetic breath studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163413/),,155.14,241024,DB00825,Menthol
,31163413,m/,"By operating the drift tube above about 130 Td, there are characteristic product ions for menthone, menthofuran and menthol, namely m/z 155.14 (protonated menthone), m/z 151.11 (protonated menthofuran), m/z 139.15 (loss of H2O from protonated menthol) and m/z 83.09 (a fragment ion, C6H11 +, from menthol).",Proton transfer reaction time-of-flight mass spectrometric measurements of volatile compounds contained in peppermint oil capsules of relevance to real-time pharmacokinetic breath studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163413/),,151.11,241025,DB00825,Menthol
,31163413,m/z,"By operating the drift tube above about 130 Td, there are characteristic product ions for menthone, menthofuran and menthol, namely m/z 155.14 (protonated menthone), m/z 151.11 (protonated menthofuran), m/z 139.15 (loss of H2O from protonated menthol) and m/z 83.09 (a fragment ion, C6H11 +, from menthol).",Proton transfer reaction time-of-flight mass spectrometric measurements of volatile compounds contained in peppermint oil capsules of relevance to real-time pharmacokinetic breath studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163413/),,139.15,241026,DB00825,Menthol
,31163413,m,"By operating the drift tube above about 130 Td, there are characteristic product ions for menthone, menthofuran and menthol, namely m/z 155.14 (protonated menthone), m/z 151.11 (protonated menthofuran), m/z 139.15 (loss of H2O from protonated menthol) and m/z 83.09 (a fragment ion, C6H11 +, from menthol).",Proton transfer reaction time-of-flight mass spectrometric measurements of volatile compounds contained in peppermint oil capsules of relevance to real-time pharmacokinetic breath studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31163413/),,83.09,241027,DB00825,Menthol
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],0.89,246053,DB00825,Menthol
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],0.84,246054,DB00825,Menthol
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],1.47,246055,DB00825,Menthol
,17049426,area under the curve (AUC),"The results showed that the area under the curve (AUC) value in cerebellar nuclei (2283.51+/-34.54 min ng/ml) following i.n. administration (+BMEM) was significantly larger than those (AUC(olfactory)=1141.92+/-26.42 min ng/ml; AUC(cerebellar)=1364.62+/-19.35 min ng/ml) after intravenous (i.v.) bolus, respectively.",Delivery of 125I-cobrotoxin after intranasal administration to the brain: a microdialysis study in freely moving rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17049426/),[min·ng] / [ml],2283.51,249349,DB00825,Menthol
,17049426,AUC,"The results showed that the area under the curve (AUC) value in cerebellar nuclei (2283.51+/-34.54 min ng/ml) following i.n. administration (+BMEM) was significantly larger than those (AUC(olfactory)=1141.92+/-26.42 min ng/ml; AUC(cerebellar)=1364.62+/-19.35 min ng/ml) after intravenous (i.v.) bolus, respectively.",Delivery of 125I-cobrotoxin after intranasal administration to the brain: a microdialysis study in freely moving rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17049426/),[min·ng] / [ml],1141.92,249350,DB00825,Menthol
,17049426,AUC,"The results showed that the area under the curve (AUC) value in cerebellar nuclei (2283.51+/-34.54 min ng/ml) following i.n. administration (+BMEM) was significantly larger than those (AUC(olfactory)=1141.92+/-26.42 min ng/ml; AUC(cerebellar)=1364.62+/-19.35 min ng/ml) after intravenous (i.v.) bolus, respectively.",Delivery of 125I-cobrotoxin after intranasal administration to the brain: a microdialysis study in freely moving rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17049426/),[min·ng] / [ml],1364.62,249351,DB00825,Menthol
,17049426,time value to peak concentration,"Also, following i.n. application (+BMEM) the measured time value to peak concentration in cerebellar nuclei (85 min) was statistically longer than that in olfactory bulb (75 min), which could be plausibly an indication for NT-I delivery into brain via nose-brain pathway in the presence of absorption enhancer.",Delivery of 125I-cobrotoxin after intranasal administration to the brain: a microdialysis study in freely moving rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17049426/),min,85,249352,DB00825,Menthol
,17049426,time value to peak concentration,"Also, following i.n. application (+BMEM) the measured time value to peak concentration in cerebellar nuclei (85 min) was statistically longer than that in olfactory bulb (75 min), which could be plausibly an indication for NT-I delivery into brain via nose-brain pathway in the presence of absorption enhancer.",Delivery of 125I-cobrotoxin after intranasal administration to the brain: a microdialysis study in freely moving rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17049426/),min,75,249353,DB00825,Menthol
,15342616,maximum plasma concentrations (Cmax,"For the 8-patch group, the average maximum plasma concentrations (Cmax +/- SD) were 41.0 +/- 5.8 ng/mL, 31.9 +/- 8.8 ng/mL, and 29.5 +/- 10.5 ng/mL for camphor, menthol, and methyl salicylate, respectively.","Dermal absorption of camphor, menthol, and methyl salicylate in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342616/),[ng] / [ml],41.0,249832,DB00825,Menthol
,15342616,maximum plasma concentrations (Cmax,"For the 8-patch group, the average maximum plasma concentrations (Cmax +/- SD) were 41.0 +/- 5.8 ng/mL, 31.9 +/- 8.8 ng/mL, and 29.5 +/- 10.5 ng/mL for camphor, menthol, and methyl salicylate, respectively.","Dermal absorption of camphor, menthol, and methyl salicylate in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342616/),[ng] / [ml],31.9,249833,DB00825,Menthol
,15342616,maximum plasma concentrations (Cmax,"For the 8-patch group, the average maximum plasma concentrations (Cmax +/- SD) were 41.0 +/- 5.8 ng/mL, 31.9 +/- 8.8 ng/mL, and 29.5 +/- 10.5 ng/mL for camphor, menthol, and methyl salicylate, respectively.","Dermal absorption of camphor, menthol, and methyl salicylate in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342616/),[ng] / [ml],29.5,249834,DB00825,Menthol
,15342616,terminal half-lives,"The harmonic mean terminal half-lives were 5.6 +/- 1.3 hours, 4.7 +/- 1.6 hours, and 3.0 +/- 1.2 hours for camphor, menthol, and methyl salicylate, respectively.","Dermal absorption of camphor, menthol, and methyl salicylate in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342616/),h,5.6,249835,DB00825,Menthol
,15342616,terminal half-lives,"The harmonic mean terminal half-lives were 5.6 +/- 1.3 hours, 4.7 +/- 1.6 hours, and 3.0 +/- 1.2 hours for camphor, menthol, and methyl salicylate, respectively.","Dermal absorption of camphor, menthol, and methyl salicylate in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342616/),h,4.7,249836,DB00825,Menthol
,15342616,terminal half-lives,"The harmonic mean terminal half-lives were 5.6 +/- 1.3 hours, 4.7 +/- 1.6 hours, and 3.0 +/- 1.2 hours for camphor, menthol, and methyl salicylate, respectively.","Dermal absorption of camphor, menthol, and methyl salicylate in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342616/),h,3.0,249837,DB00825,Menthol
,29716869,relative bioavailability,"A combination of 6% menthol and 6% PG exhibited highest RIS in vitro penetration rate and showed a high efficiency in vivo, with a relative bioavailability of 131.53% compared with intragastric administration.",Delivery of risperidone from gels across porcine skin in vitro and in vivo in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716869/),%,131.53,258368,DB00825,Menthol
,14698588,maximum solubility,"The poloxamer gel with menthol/ibuprofen ratio of 1:9 and higher than 15% poloxamer 188 showed the maximum solubility of ibuprofen, 1.2mg/ml.",Enhanced rectal bioavailability of ibuprofen in rats by poloxamer 188 and menthol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14698588/),[mg] / [ml],1.2,264524,DB00825,Menthol
,28283988,Apparent nicotine clearance,Apparent nicotine clearance was typically 0.407 L/min in males and 26% higher in females (68% inter-individual variability).,Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283988/),[l] / [min],0.407,266174,DB00825,Menthol
,28283988,initial,"The typical initial and terminal half-lives were 1.35 and 17 h, respectively.",Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283988/),h,1.35,266175,DB00825,Menthol
,28283988,terminal half-lives,"The typical initial and terminal half-lives were 1.35 and 17 h, respectively.",Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283988/),h,17,266176,DB00825,Menthol
